---

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

Form 8-K

 

---

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

July 6, 2004

Date of Report

(Date of earliest event reported)

 

---

 

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

 

---

 

Delaware		000-31615		94-3297098
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

10240 Bubb Road

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

 

(408) 777-1417

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

---

---

Item 5. Other Events and Required FD Disclosure.

 

On July 6, 2004, DURECT Corporation, a Delaware corporation (“DURECT”), announced positive clinical results with its ORADUR^™ sustained release oral gel-cap technology.

 

A copy of DURECT’s press release announcing positive clinical results with its ORADUR^™ sustained release oral gel-cap technology is attached as Exhibit 99.1 hereto and incorporated by reference herein.

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		DURECT Corporation
Date: July 6, 2004		By:		/s/ James E. Brown
				James E. Brown
				President and Chief Executive Officer

 

---

DURECT CORPORATION

 

INDEX TO EXHIBITS

 

Exhibit Number		Description
99.1		Press Release of DURECT Corporation dated July 6, 2004